These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 25039318)

  • 21. Effect of a long-term oral l-arginine supplementation on glucose metabolism: a randomized, double-blind, placebo-controlled trial.
    Monti LD; Setola E; Lucotti PC; Marrocco-Trischitta MM; Comola M; Galluccio E; Poggi A; Mammì S; Catapano AL; Comi G; Chiesa R; Bosi E; Piatti PM
    Diabetes Obes Metab; 2012 Oct; 14(10):893-900. PubMed ID: 22553931
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liraglutide and the preservation of pancreatic β-cell function in early type 2 diabetes: the LIBRA trial.
    Retnakaran R; Kramer CK; Choi H; Swaminathan B; Zinman B
    Diabetes Care; 2014 Dec; 37(12):3270-8. PubMed ID: 25249651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of miR-153, an IL-1β-responsive miRNA, prevents beta cell failure and inflammation-associated diabetes.
    Sun Y; Zhou S; Shi Y; Zhou Y; Zhang Y; Liu K; Zhu Y; Han X
    Metabolism; 2020 Oct; 111():154335. PubMed ID: 32795559
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance.
    Cavaghan MK; Ehrmann DA; Byrne MM; Polonsky KS
    J Clin Invest; 1997 Aug; 100(3):530-7. PubMed ID: 9239399
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of the urotensin-II receptor antagonist palosuran on secretion of and sensitivity to insulin in patients with Type 2 diabetes mellitus.
    Sidharta PN; Rave K; Heinemann L; Chiossi E; Krähenbühl S; Dingemanse J
    Br J Clin Pharmacol; 2009 Oct; 68(4):502-10. PubMed ID: 19843053
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus.
    Schwartz EA; Koska J; Mullin MP; Syoufi I; Schwenke DC; Reaven PD
    Atherosclerosis; 2010 Sep; 212(1):217-22. PubMed ID: 20557887
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The antiinflammatory cytokine interleukin-1 receptor antagonist protects from high-fat diet-induced hyperglycemia.
    Sauter NS; Schulthess FT; Galasso R; Castellani LW; Maedler K
    Endocrinology; 2008 May; 149(5):2208-18. PubMed ID: 18239070
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Evaluation of islet beta cell function in subjects with normal glucose tolerance, impaired glucose regulation, and type 2 diabetes mellitus].
    Liu J; Li YB; Shao H; Li YX; Yuan YH; Xiao YB; Weng JP
    Zhonghua Yi Xue Za Zhi; 2007 May; 87(18):1252-5. PubMed ID: 17686259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rosiglitazone improves insulin sensitivity in nonobese subjects with impaired glucose tolerance: the role of adiponectin and C-reactive protein.
    Hung YJ; Lin SH; Pei D; Kuo SW; Hsieh CH; He CT; Hsing Lee C; Fan SC; Sheu WH
    Metabolism; 2006 Apr; 55(4):439-44. PubMed ID: 16546473
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Repaglinide treatment amplifies first-phase insulin secretion and high-frequency pulsatile insulin release in Type 2 diabetes.
    Hollingdal M; Sturis J; Gall MA; Damsbo P; Pincus S; Veldhuis JD; Pørksen N; Schmitz O; Juhl CB
    Diabet Med; 2005 Oct; 22(10):1408-13. PubMed ID: 16176204
    [TBL] [Abstract][Full Text] [Related]  

  • 31. β Cell-Specific Deletion of the IL-1 Receptor Antagonist Impairs β Cell Proliferation and Insulin Secretion.
    Böni-Schnetzler M; Häuselmann SP; Dalmas E; Meier DT; Thienel C; Traub S; Schulze F; Steiger L; Dror E; Martin P; Herrera PL; Gabay C; Donath MY
    Cell Rep; 2018 Feb; 22(7):1774-1786. PubMed ID: 29444430
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients.
    Muscelli E; Mari A; Casolaro A; Camastra S; Seghieri G; Gastaldelli A; Holst JJ; Ferrannini E
    Diabetes; 2008 May; 57(5):1340-8. PubMed ID: 18162504
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of sugar-sweetened beverage intake on the development of type 2 diabetes mellitus in subjects with impaired glucose tolerance: the Mihama diabetes prevention study.
    Teshima N; Shimo M; Miyazawa K; Konegawa S; Matsumoto A; Onishi Y; Sasaki R; Suzuki T; Yano Y; Matsumoto K; Yamada T; Gabazza EC; Takei Y; Sumida Y
    J Nutr Sci Vitaminol (Tokyo); 2015; 61(1):14-9. PubMed ID: 25994135
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved glycemic control enhances the incretin effect in patients with type 2 diabetes.
    An Z; Prigeon RL; D'Alessio DA
    J Clin Endocrinol Metab; 2013 Dec; 98(12):4702-8. PubMed ID: 24092826
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hyperbolic relationship between insulin secretion and sensitivity on oral glucose tolerance test.
    Retnakaran R; Shen S; Hanley AJ; Vuksan V; Hamilton JK; Zinman B
    Obesity (Silver Spring); 2008 Aug; 16(8):1901-7. PubMed ID: 18551118
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Beta cell response to oral glimepiride administration during and following a hyperglycaemic clamp in NIDDM patients.
    van der Wal PS; Draeger KE; van Iperen AM; Martini C; Aarsen M; Heine RJ
    Diabet Med; 1997 Jul; 14(7):556-63. PubMed ID: 9223393
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor, Improves Early-Phase Insulin Secretion in Drug-Naïve Patients with Type 2 Diabetes.
    Ito R; Fukui T; Hayashi T; Osamura A; Ohara M; Hara N; Higuchi A; Yamamoto T; Hirano T
    Drugs R D; 2015 Sep; 15(3):245-51. PubMed ID: 26224337
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus.
    Aaboe K; Knop FK; Vilsbøll T; Deacon CF; Holst JJ; Madsbad S; Krarup T
    Diabetes Obes Metab; 2010 Apr; 12(4):323-33. PubMed ID: 20380653
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acute disruption of glucagon secretion or action does not improve glucose tolerance in an insulin-deficient mouse model of diabetes.
    Steenberg VR; Jensen SM; Pedersen J; Madsen AN; Windeløv JA; Holst B; Quistorff B; Poulsen SS; Holst JJ
    Diabetologia; 2016 Feb; 59(2):363-70. PubMed ID: 26537124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sfrp5 associates with beta-cell function in humans.
    Carstensen-Kirberg M; Hatziagelaki E; Tsiavou A; Chounta A; Nowotny P; Pacini G; Dimitriadis G; Roden M; Herder C
    Eur J Clin Invest; 2016 Jun; 46(6):535-43. PubMed ID: 27019073
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.